Skip to main content

Table 3 Predictors of allopurinol use among respondents with gout

From: Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study

Predictor

Contrast, dy/dx (95% CI)

p value

Female vs male

 Never vs ever

0.312 (0.021, 0.604)

0.036

 Prior vs current

0.083 (−0.158, 0.324)

0.50

 Joint test

 

0.037

Age

 Never vs ever

0.002 (− 0.006, 0.010)

0.66

 Prior vs current

−0.003 (− 0.011, 0.005)

0.53

 Joint test

 

0.80

BMI

 Never vs ever

0.007 (−0.017, 0.030)

0.57

 Prior vs current

−0.022 (− 0.039, − 0.004)

0.015

 Joint test

 

0.043

IRSAD (SES)

 Never vs ever

0.002 (0.000, 0.003)

0.006

 Prior vs current

−0.001 (− 0.002, 0.000)

0.15

 Joint test

 

0.017

Cholesterol medication

 Never vs ever

−0.314 (− 0.529, − 0.100)

0.004

 Prior vs current

− 0.142 (− 0.435, 0.151)

0.34

 Joint test

 

0.010

  1. Allopurinol use was classified into three categories: “Never”, “Prior”, and “Current”. Analysis was performed by multinomial logistic regression, and interpreted using the change in the predicted population-averaged marginal probabilities of each allopurinol category with a one unit change in the predictor variable (dy/dx). Helmert contrasts of these dy/dx values were used to interpret the results in terms of “Never vs Ever” and “Prior vs Current” allopurinol use
  2. BMI body mass index, IRSAD Index of Relative Social Advantage and Disadvantage, SES socioeconomic status
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us